Albumin-binding lipid-aptamer conjugates for cancer immunoimaging and immunotherapy

作     者：onglong Tian Ming Shao Yimou Gong Yu Chao Ting Wei Kai Yang Qian Chen Zhuang Liu Longlong Tian;Ming Shao;Yimou Gong;Yu Chao;Ting Wei;Kai Yang;Qian Chen;Zhuang Liu

作者机构：Institute of Molecular MedicineRenji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China Institute of Functional Nano and Soft Materials(FUNSOM)Jiangsu Key Laboratory for Carbon-Based Functional Materials and DevicesSoochow UniversitySuzhou 215123China Frontiers Science Center for Rare IsotopesLanzhou UniversityLanzhou 730000China State Key Laboratory of Radiation Medicine and ProtectionSchool of Radiation Medicine and Protection&School for Radiological and Interdisciplinary Sciences(RAD-X)Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education InstitutionsSoochow UniversitySuzhou 215123China 

出 版 物：《Science China Chemistry》 (中国科学（化学英文版）)

年 卷 期：2022年第65卷第3期

页      面：574-583页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 1010[医学-医学技术（可授医学、理学学位）] 100214[医学-肿瘤学] 0703[理学-化学] 10[医学] 1009[医学-特种医学] 

基　　金：supported by the National Natural Science Foundation of China (32101149, 91959104, 21927803, 52032008, 51903182, 51572180) the China Postdoctoral Science Foundation (2020M671143) a Project Funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions, Jiangsu Social Development Project (BE2019658) Suzhou Key Laboratory of Nanotechnology and Biomedicine Collaborative Innovation Center of Suzhou Nano Science & Technology the Program of Introducing Talents of Discipline to Universities of China。 

主　　题：aptamer immunoimaging immunotherapy 

摘      要：Monitoring dynamic changes in tumor immune markers are essential for predicting the therapeutic responses of tumors to immunotherapy, as well as other traditional therapies, such as chemotherapy and radiotherapy. Here, we designed a lipid-aptamer conjugate by employing a C18 chain to modify an aptamer targeting programmed cell death-ligand 1(C18-ap PDL1). The obtained C18-ap PDL1 could bind with serum albumin postintravenous injection to achieve prolonged blood circulation and enhanced in vivo stability without weakening its binding affinity toward PDL1. C18-ap PDL1 labeling with radionuclides, such as;Tc, could yield a nuclear imaging agent exhibiting much higher tumor-homing ability than bare aptamer. Notably, such radiolabeled C18-ap PDL1 could be utilized to visually monitor the dynamic changes in PDL1 expression postchemotherapy or radiotherapy within a few hours. Additionally, this C18-ap PDL1 could offer improved antitumor immune therapeutic responses,which are comparable with those of commercial anti-PDL1 antibodies at the same weight dosage. Thus, this article presented promising lipid-modified aptamers for cancer immunoimaging and immunotherapy.